References
- Martelletti P , BirbeckGL, KatsaravaZ, JensenRH, StovnerLJ, SteinerTJ. The global burden of disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J. Headache Pain.14(1) , 13 (2013).
- Cutrer F , SmithJ. Human studies in the pathophysiology of migraine: genetics and functional neuroimaging. Headache53(2) , 401–412 (2013).
- Schurks M . Genetics of migraine in the age of genome-wide association studies. J. Headache Pain13(1) , 1–9 (2012).
- Anttila V , StefanssonH, KallelaM et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat. Genet. 42(10) , 869–873 (2010).
- Chasman DI , SchurksM, AnttilaV et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat. Genet. 43(7) , 695–698 (2011).
- Ligthart L , de Vries B, Smith AV et al. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur. J. Hum. Genet.19(8) , 901–907 (2011).
- Luykx J , MasonM, FerrariMD et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin. Pharmacol. Ther. 85(3) , 283–288 (2009).
- Di L orenzo C, Grieco G, Santorelli F. Migraine headache: a review of the molecular genetics of a common disorder. J. Headache Pain13(7) , 571–580 (2012).
- Roses A . Pharmacogenetics and the practice of medicine. Nature405(6788) , 857–865 (2000).
- Liberati A , AltmanDG, TetzlaffJ et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339 , b2700 (2009).
- Evers S , AfraJ, FreseA et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur. J. Neurol. 16(9) , 968–981 (2009).
- Silberstein SD , HollandS, FreitagF et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology 78(17) , 1337–1345 (2012).
- Sarchielli P , GranellaF, PrudenzanoMP et al. Italian guidelines for primary headaches: 2012 revised version. J. Headache Pain 13(Suppl. 2) , S31–S70 (2012).
- Pringsheim T , DavenportW, MackieG et al. Canadian headache society guideline for migraine prophylaxis. Can. J. Neurol. Sci. 39(2 Suppl. 2) , S1–S59 (2012).
- Ishii M , SakairiY, HaraH et al. Negative predictors of clinical response to triptans in patients with migraine. Neurol. Sci. 33(2) , 453–461 (2012).
- Maassen VanDenBrink A , VergouweMN, OphoffRA et al. Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am. J. Med. Genet. 77(5) , 415–420 (1998).
- Maassen VanDenBrink A , VergouweMN, OphoffRA, SaxenaPR, FerrariMD, FrantsRR. 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache38(4) , 288–291 (1998).
- Mehrotra S , VanmolkotKR, FrantsRR et al. The Phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan. Headache 47(5) , 711–716 (2007).
- Fernandez F , ColsonNJ, GriffithsLR. Pharmacogenetics of migraine: genetic variants and their potential role in migraine therapy. Pharmacogenomics8(6) , 609–622 (2007).
- Gentile G , BorroM, SimmacoM et al. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin. Drug Metab. Toxicol. 7(1) , 39–47 (2011).
- Johnson MP , FernandezF, ColsonNJ et al. A pharmacogenomic evaluation of migraine therapy. Expert Opin. Pharmacother. 8(12) , 1821–1835 (2007).
- Montagna P . Recent advances in the pharmacogenomics of pain and headache. Neurol.Sci.28(Suppl. 2) , S208–S212 (2007).
- Ophoff RA , van den Maagdenberg AM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur. J. Pharmacol.413(1) , 1–10 (2001).
- Piane M , LulliP, FarinelliI et al. Genetics of migraine and pharmacogenomics: some considerations. J. Headache Pain 8(6) , 334–339 (2007).
- Rogers KL , LeaRA, GriffithsLR. Molecular mechanisms of migraine: prospects for pharmacogenomics. Am. J. Pharmacogenomics3(5) , 329–343 (2003).
- Simmaco M , BorroM, MissoriS et al. Pharmacogenomics in migraine: catching biomarkers for a predictable disease control [corrected]. Expert Rev. Neurother. 9(6) , 1267–1269 (2009).
- Tfelt-Hansen P , BrosenK. Pharmacogenomics and migraine: possible implications. J. Headache Pain9(1) , 13–18 (2008).
- Gentile G , BorroM, LalaN et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J. Headache Pain 11(5) , 431–435 (2010).
- Asuni C , CherchiA, CongiuD et al. Association study between clinical response to rizatriptan and some candidate genes. J. Headache Pain 8(3) , 185–189 (2007).
- Di Lorenzo C , PierelliF, CoppolaG et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 721(18) , 1588–1594 (2009).
- Tronvik E , StovnerLJ, BovimG et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol. 8 , 4 (2008).
- Terrazzino S , VianaM, FloriddiaE et al. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur. J. Pharmacol. 641(2–3) , 82–87 (2010).
- Velati D , VianaM, CrestaS et al. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur. J. Pharmacol. 580(1–2) , 43–47 (2008).
- Terrazzino S , TassorelliC, SancesG et al. Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. Eur. J. Neurol. 19(1) , 69–75 (2012).
- Terrazzino S , SancesG, BalsamoF et al. Role of 2 common variants of 5HT2A gene in medication overuse headache. Headache 50(10) , 1587–1596 (2010).
- Di L orenzo C, Di Lorenzo G, Sances G et al. Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. J. Headache Pain10(5) , 349–355 (2009).
- Di Lorenzo C , SancesG, Di Lorenzo G et al. The wolframin His611Arg polymorphism influences medication overuse headache. Neurosci. Lett.424(3) , 179–184 (2007).
- Tronvik E , StovnerLJ, HeldeG et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289(1) , 65–69 (2003).
- Schrader H , StovnerLJ, HeldeG et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 322(7277) , 19–22 (2001).
- Hanley MJ , AbernethyDR, GreenblattDJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet.49(2) , 71–87 (2010).
- Bigal M , LiptonR, HollandP, GoadsbyP. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology68(21) , 1851–1861 (2007).
- Ligthart L , HottengaJJ, LewisCM et al. Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders. Hum. Genet. 133(2) , 173–186 (2014).
- Freilinger T , AnttilaV, de Vries B et al. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat. Genet.44(7) , 777–782 (2012).
- Maggo SD , KennedyMA, ClarkDW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf.34(1) , 1–19 (2011).
- Viana M , GenazzaniA, TerrazzinoS et al. Triptan non-responders: do they exist and who are they? Cephalalgia 33(11) , 891–896 (2013).
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition (beta version). Cephalalgia33(9) , 629–808 (2013).
- Di Lorenzo C , Di Lorenzo G, Santorelli FM. Pharmacogenomics and medication overuse headache: when the cure may turn to poison. Pharmacogenomics10(10) , 1557–1559 (2009).